Reference Interval:
None Detected
|
| Interpretive Data: |
ANA Specimens are screened using enzyme-linked immunosorbent assay (ELISA) methodology. All ELISA results reported as Detected are further tested by indirect fluorescent assay (IFA) using HEp-2 substrate with an IgG-specific conjugate. The ANA ELISA screen is designed to detect antibodies against dsDNA, histone, SS-A (Ro), SS-B (La), Smith, snRNP/Sm, Scl-70, Jo-1, centromere, and an extract of lysed HEp-2 cells. ANA ELISA assays have been reported to have lower sensitivities for antibodies associated with nucleolar and speckled ANA-IFA patterns.
|
| Note: |
When cell culture substrates (HEp-2 cells) are used, the ANA incidence is greater than 90 percent in systemic lupus erythematosus (SLE), 80 percent in Sjsyndrome and scleroderma, and 40 percent in juvenile idiopathic arthritis.
ARUP uses anti-human IgG conjugate since many (20-77 percent) healthy individuals have low levels (1:40 to 1:80) of ANA-IgM. Conversion of ANAs from IgM to IgG generally precedes the onset of autoimmune disease states. If clinical presentation is inconsistent with the ANA IFA result, consult ARUP for alternative testing.
If ANA antibodies are detected by ELISA, then an IFA titer will be added. Additional charges apply
|
| CPT Code(s): |
86038 ANA; if reflexed, add 86039 ANA titer
|
Cross References: |
ANA Screen (Anti-Nuclear Antibodies (ANA), IgG by ELISA with Reflex to ANA, IgG by IFA), ANA, IgG (Anti-Nuclear Antibodies (ANA), IgG by ELISA with Reflex to ANA, IgG by IFA), Antinuclear Antibodies (ANA), Hep-2 Substrate, Serum (Anti-Nuclear Antibodies (ANA), IgG by ELISA with Reflex to ANA, IgG by IFA)
, Antinuclear Antibodies, IgG (Anti-Nuclear Antibodies (ANA), IgG by ELISA with Reflex to ANA, IgG by), Nuclear Antibodies, IgG (Anti-Nuclear Antibodies (ANA), IgG by ELISA with Reflex to ANA, IgG by IFA) |
|